Latest News

March 2020

COVID-19 Pneumonia: Procalcitonin (PCT) for Risk Assessment and Rule-out of Bacterial Coinfection

The biomarker Procalcitonin (PCT) is widely used to assess the risk of bacterial infection and progression to severe sepsis and septic shock in conjunction with other laboratory findings and clinical assessment.
Further, the change of PCT over time is used to determine the mortality risk.
In patients with suspected or confirmed lower respiratory tract infections (LRTI), including community-acquired pneumonia (CAP), acute bronchitis and acute exacerbations of COPD (AECOPD), PCT is an aid in decision making on antibiotic therapy for inpatients or patients in the emergency department (ED).

Procalcitonin has now been shown to be also a valuable tool in the current COVID-19 pandemic to early identify patients at low risk for bacterial coinfection and adverse outcome...

COVID-19 Pneumonia: Procalcitonin (PCT) for Risk Assessment and Rule-out of Bacterial Coinfection >


News Archive

thermo scientific applied biosystems invitrogen fisher scientific unity lab service